Source: eKapija | Tuesday, 11.06.2019.| 11:40
Highlight an article Print out the news

Through joint efforts to 80 innovative latest-generation medical drugs

(Photo: Pavel Kubarkov/shutterstock.com)
Representatives of the National Health Insurance Fund (NHIF), the Ministry of Health, the Ministry of Finance and manufacturers of innovative medical drugs, members of the Inovia association, discussed the concrete steps to be taken in order to make considerable progress when it comes to the availability of the most efficient therapies to patients in Serbia by the end of 2019.

Thanks to the joint efforts of state institutions and producers of innovative medical drugs, patients are expected to be provided with more than 80 innovative medical drugs of the latest generation, primarily for the most serious diseases, at the state's expense in 2019 or 2020 at the latest.

This will make help address the problem of Serbia being late in providing innovative medical drugs to those with health insurance, INOVIA says on its website.

– In the past years, the state has started making visible progress in that respect, putting dozens of new innovative medical drugs on the reimbursement list, while also securing stability in medical drug supply by regularly paying their obligations toward the suppliers. Pharmaceutical companies, members of Inovia, on the other hand, have shown an understanding regarding the needs of patients and the economic limits of the state, making great efforts to provide medical drugs at considerably more favorable conditions. The delay in putting innovative medical drugs on the reimbursement list on the one hand and the quick development of innovative therapies on the other are the main causes for the lateness in introducing innovative therapies – the press release reads.

It was pointed out during the conversation that stability and predictability, as well as the strengthening of the partnership of the state and the innovative pharmaceutical industry in the upcoming years might result in considerable improvement of access to innovative therapies, which is the common interest of the state, the innovative pharmaceutical industry and the patients themselves.
Only logged-in users can comment.